Existing treatments for Dravet include Jazz Pharmaceuticals’ Epidiolex and UCB’s Fintepla, but none of the approved products address the underlying genetic cause of the syndrome. Similarly ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the comp ...

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...

Study: Neonatal but not Juvenile Gene Therapy Reduces Seizures and Prolongs Lifespan in SCN1B-Dravet Syndrome Mice. Image Credit: Natali _ Mis/Shutterstock.com Developmental and epileptic ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions ...

(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics, Inc. (STOK) Tuesday announced partnership to develop and sell zorevunersen, Stoke's drug candidate for the treatment of Dravet syndrome ...

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...